218 related articles for article (PubMed ID: 24957886)
61. Combined detection of serum autoantibodies as diagnostic biomarkers in esophagogastric junction adenocarcinoma.
Xu YW; Chen H; Guo HP; Yang SH; Luo YH; Liu CT; Huang XY; Tang XM; Hong CQ; Li EM; Xu LY; Peng YH
Gastric Cancer; 2019 May; 22(3):546-557. PubMed ID: 30426295
[TBL] [Abstract][Full Text] [Related]
62. Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer.
Zhu Y; Guo M; Zhang L; Xu T; Wang L; Xu G
Oncol Rep; 2016 Jan; 35(1):454-62. PubMed ID: 26531769
[TBL] [Abstract][Full Text] [Related]
63. Usefulness of Salivary and Serum Auto-antibodies Against Tumor Biomarkers HER2 and MUC1 in Breast Cancer Screening.
Laidi F; Bouziane A; Errachid A; Zaoui F
Asian Pac J Cancer Prev; 2016; 17(1):335-9. PubMed ID: 26838233
[TBL] [Abstract][Full Text] [Related]
64. Breast cancer detection of large size to DCIS by hypoxia and angiogenesis using NIRS.
Nioka S; Shnall M; Conant E; Wang SC; Reynolds VB; Ching BC; Swan JHT; Chung PC; Cheng L; Shieh D; Lin Y; Chung C; Tseng SH; Chance B
Adv Exp Med Biol; 2013; 789():211-219. PubMed ID: 23852497
[TBL] [Abstract][Full Text] [Related]
65. Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer.
Zuo X; Chen L; Liu L; Zhang Z; Zhang X; Yu Q; Feng L; Zhao X; Qin T
Tumour Biol; 2016 Jan; 37(1):1309-17. PubMed ID: 26289852
[TBL] [Abstract][Full Text] [Related]
66. Evolving paradigm for imaging, diagnosis, and management of DCIS.
Wells CJ; O'Donoghue C; Ojeda-Fournier H; Retallack HE; Esserman LJ
J Am Coll Radiol; 2013 Dec; 10(12):918-23. PubMed ID: 24295941
[TBL] [Abstract][Full Text] [Related]
67. Determination of placental ferritin-positive peripheral lymphocytes in early stages of breast cancer.
Rosen HR; Stierer M; Göttlicher J; Wolf H; Spoula H; Eibl M
Am J Surg; 1993 Feb; 165(2):213-7. PubMed ID: 8427398
[TBL] [Abstract][Full Text] [Related]
68. Photoacoustic mammography: initial clinical results.
Kitai T; Torii M; Sugie T; Kanao S; Mikami Y; Shiina T; Toi M
Breast Cancer; 2014 Mar; 21(2):146-53. PubMed ID: 22484692
[TBL] [Abstract][Full Text] [Related]
69. Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer.
Shan M; Yin H; Li J; Li X; Wang D; Su Y; Niu M; Zhong Z; Wang J; Zhang X; Kang W; Pang D
Oncotarget; 2016 Apr; 7(14):18485-94. PubMed ID: 26918343
[TBL] [Abstract][Full Text] [Related]
70. Circulating levels of endothelin-1 (ET-1) and its precursor (Big ET-1) in breast cancer early diagnosis.
Kalles V; Zografos GC; Provatopoulou X; Kalogera E; Liakou P; Georgiou G; Sagkriotis A; Nonni A; Gounaris A
Tumour Biol; 2012 Aug; 33(4):1231-6. PubMed ID: 22415226
[TBL] [Abstract][Full Text] [Related]
71. Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality.
Evans RL; Pottala JV; Nagata S; Egland KA
BMC Cancer; 2018 Jan; 18(1):119. PubMed ID: 29386014
[TBL] [Abstract][Full Text] [Related]
72. Decreased breast cancer tumor size, stage, and mortality in Rhode Island: an example of a well-screened population.
Coburn NG; Chung MA; Fulton J; Cady B
Cancer Control; 2004; 11(4):222-30. PubMed ID: 15284713
[TBL] [Abstract][Full Text] [Related]
73. Ductal carcinoma in situ of the breast: can biomarkers improve current management?
Bartlett JM; Nofech-Moses S; Rakovitch E
Clin Chem; 2014 Jan; 60(1):60-7. PubMed ID: 24262106
[TBL] [Abstract][Full Text] [Related]
74. Stage of breast cancer at diagnosis among low-income women with access to mammography.
Lobb R; Ayanian JZ; Allen JD; Emmons KM
Cancer; 2010 Dec; 116(23):5487-96. PubMed ID: 21171232
[TBL] [Abstract][Full Text] [Related]
75. Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer.
Burford B; Gentry-Maharaj A; Graham R; Allen D; Pedersen JW; Nudelman AS; Blixt O; Fourkala EO; Bueti D; Dawnay A; Ford J; Desai R; David L; Trinder P; Acres B; Schwientek T; Gammerman A; Reis CA; Silva L; Osório H; Hallett R; Wandall HH; Mandel U; Hollingsworth MA; Jacobs I; Fentiman I; Clausen H; Taylor-Papadimitriou J; Menon U; Burchell JM
Br J Cancer; 2013 May; 108(10):2045-55. PubMed ID: 23652307
[TBL] [Abstract][Full Text] [Related]
76. Individual and combined usefulness of lipid associated sialic acid, mucoid proteins and hexoses as tumor markers in breast carcinoma.
Patel PS; Baxi BR; Adhvaryu SG; Balar DB
Cancer Lett; 1990 Jun; 51(3):203-8. PubMed ID: 2161706
[TBL] [Abstract][Full Text] [Related]
77. Can serum autoantibodies be a potential early detection biomarker for breast cancer in women? A diagnostic test accuracy review and meta-analysis.
Kathrikolly T; Nair SN; Mathew A; Saxena PPU; Nair S
Syst Rev; 2022 Oct; 11(1):215. PubMed ID: 36210467
[TBL] [Abstract][Full Text] [Related]
78. Prospective validation of a blood-based 9-miRNA profile for early detection of breast cancer in a cohort of women examined by clinical mammography.
Lyng MB; Kodahl AR; Binder H; Ditzel HJ
Mol Oncol; 2016 Dec; 10(10):1621-1626. PubMed ID: 27839676
[TBL] [Abstract][Full Text] [Related]
79. Circulating Bone-related Markers and YKL-40 Versus HER2 and TOPO2a in Bone Metastatic and Nonmetastatic Breast Cancer: Diagnostic Implications.
Shaker OG; Helmy HS
Clin Breast Cancer; 2018 Jun; 18(3):e321-e328. PubMed ID: 28645722
[TBL] [Abstract][Full Text] [Related]
80. Autoantibodies as potential biomarkers for breast cancer.
Zhong L; Ge K; Zu JC; Zhao LH; Shen WK; Wang JF; Zhang XG; Gao X; Hu W; Yen Y; Kernstine KH
Breast Cancer Res; 2008; 10(3):R40. PubMed ID: 18460216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
